144 related articles for article (PubMed ID: 38100217)
21. How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia.
Maiti A; Konopleva MY
Cancer J; 2022 Jan-Feb 01; 28(1):2-13. PubMed ID: 35072368
[TBL] [Abstract][Full Text] [Related]
22. Hypomethylating agents and venetoclax in acute myeloid leukemia.
DiNardo CD
Clin Adv Hematol Oncol; 2021 Feb; 19(2):82-83. PubMed ID: 33596188
[No Abstract] [Full Text] [Related]
23. Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia.
Matthews AH; Perl AE; Luger SM; Gill SI; Lai C; Porter DL; Skuli S; Bruno XJ; Carroll MP; Freyer CW; Carulli A; Babushok DV; Frey NV; Hexner EO; Martin ME; McCurdy SR; Stadtmauer EA; Loren AW; Paralkar VR; Maillard IP; Pratz KW
Am J Hematol; 2023 Aug; 98(8):1254-1264. PubMed ID: 37334852
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.
Maiti A; Rausch CR; Cortes JE; Pemmaraju N; Daver NG; Ravandi F; Garcia-Manero G; Borthakur G; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Kadia TM; Takahashi K; Yilmaz M; Jain N; Kornblau S; Montalban Bravo G; Sasaki K; Andreeff M; Bose P; Ferrajoli A; Issa GC; Jabbour EJ; Masarova L; Thompson PA; Wang S; Konoplev S; Pierce SA; Ning J; Qiao W; Welch JS; Kantarjian HM; DiNardo CD; Konopleva MY
Haematologica; 2021 Mar; 106(3):894-898. PubMed ID: 32499238
[No Abstract] [Full Text] [Related]
25. Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy.
Chua CC; Roberts AW; Reynolds J; Fong CY; Ting SB; Salmon JM; MacRaild S; Ivey A; Tiong IS; Fleming S; Brown FC; Loo S; Majewski IJ; Bohlander SK; Wei AH
J Clin Oncol; 2020 Oct; 38(30):3506-3517. PubMed ID: 32687450
[TBL] [Abstract][Full Text] [Related]
26. Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia.
Othman TA; Azenkot T; Moskoff BN; Tenold ME; Jonas BA
Future Oncol; 2021 Aug; 17(23):2989-3005. PubMed ID: 34024158
[TBL] [Abstract][Full Text] [Related]
27. Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia.
Gangat N; Johnson I; McCullough K; Farrukh F; Al-Kali A; Alkhateeb H; Begna K; Mangaonkar A; Litzow M; Hogan W; Shah M; Patnaik M; Pardanani A; Tefferi A
Haematologica; 2022 Oct; 107(10):2501-2505. PubMed ID: 35770533
[No Abstract] [Full Text] [Related]
28. Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.
Johnson IM; Karrar O; Rana M; Iftikhar M; Chen S; McCullough K; Saliba AN; Al-Kali A; Alkhateeb H; Begna K; Litzow M; Hogan WJ; Shah M; Patnaik MM; Pardanani A; Hermann J; Tefferi A; Gangat N
Br J Haematol; 2024 Apr; 204(4):1232-1237. PubMed ID: 38311378
[TBL] [Abstract][Full Text] [Related]
29. Development of a scoring system for predicting primary resistance to venetoclax plus hypomethylating agents (HMAs) in acute myeloid leukemia patients.
Zong L; Yin M; Kong J; Zhang J; Song B; Zhu J; Xue S; Wu X; Wu D; Bao X; Qiu H
Mol Carcinog; 2023 Oct; 62(10):1572-1584. PubMed ID: 37555764
[TBL] [Abstract][Full Text] [Related]
30. Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy.
Brackman D; Eckert D; Menon R; Salem AH; Potluri J; Smith BD; Wei AH; Hayslip J; Miles D; Mensing S; Gopalakrishnan S; Zha J
Hematol Oncol; 2022 Apr; 40(2):269-279. PubMed ID: 35043428
[TBL] [Abstract][Full Text] [Related]
31. Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients.
Nanaa A; He R; Foran JM; Badar T; Gangat N; Pardanani A; Hogan WJ; Litzow MR; Patnaik M; Al-Kali A; Alkhateeb HB
Br J Haematol; 2024 Jan; 204(1):171-176. PubMed ID: 37710381
[TBL] [Abstract][Full Text] [Related]
32. Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia.
Arora S; Zainaldin C; Bathini S; Gupta U; Worth S; Bachiashvili K; Bhatia R; Godby K; Jamy O; Rangaraju S; Diamond B; Oliver JD; Salzman D; Di Stasi A; Vachhani P
Leuk Res; 2022 Jun; 117():106844. PubMed ID: 35487134
[TBL] [Abstract][Full Text] [Related]
33. The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis.
Liu B; Guo Y; Deng L; Qiao Y; Jian J
Hematology; 2020 Dec; 25(1):414-423. PubMed ID: 33191860
[TBL] [Abstract][Full Text] [Related]
34. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.
Pollyea DA; Pratz K; Letai A; Jonas BA; Wei AH; Pullarkat V; Konopleva M; Thirman MJ; Arellano M; Becker PS; Chyla B; Hong WJ; Jiang Q; Potluri J; DiNardo CD
Am J Hematol; 2021 Feb; 96(2):208-217. PubMed ID: 33119898
[TBL] [Abstract][Full Text] [Related]
35. Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).
Ball BJ; Arslan S; Koller P; Ngo D; Afkhami M; Salhotra A; Al-Malki M; Aribi A; Ali H; Sandhu K; Otoukesh S; Amanam I; Pourhassan H; Artz A; Curtin P; Stein A; Nakamura R; Marcucci G; Smith E; Pullarkat V; Aldoss I
Leuk Lymphoma; 2022 Dec; 63(13):3232-3236. PubMed ID: 36089918
[No Abstract] [Full Text] [Related]
36. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use.
Mei M; Aldoss I; Marcucci G; Pullarkat V
Am J Hematol; 2019 Mar; 94(3):358-362. PubMed ID: 30499168
[TBL] [Abstract][Full Text] [Related]
37. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
DiNardo CD; Jonas BA; Pullarkat V; Thirman MJ; Garcia JS; Wei AH; Konopleva M; Döhner H; Letai A; Fenaux P; Koller E; Havelange V; Leber B; Esteve J; Wang J; Pejsa V; Hájek R; Porkka K; Illés Á; Lavie D; Lemoli RM; Yamamoto K; Yoon SS; Jang JH; Yeh SP; Turgut M; Hong WJ; Zhou Y; Potluri J; Pratz KW
N Engl J Med; 2020 Aug; 383(7):617-629. PubMed ID: 32786187
[TBL] [Abstract][Full Text] [Related]
38. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia.
Cherry EM; Abbott D; Amaya M; McMahon C; Schwartz M; Rosser J; Sato A; Schowinsky J; Inguva A; Minhajuddin M; Pei S; Stevens B; Winters A; Jordan CT; Smith C; Gutman JA; Pollyea DA
Blood Adv; 2021 Dec; 5(24):5565-5573. PubMed ID: 34610123
[TBL] [Abstract][Full Text] [Related]
39. A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.
Borthakur G; Odenike O; Aldoss I; Rizzieri DA; Prebet T; Chen C; Popovic R; Modi DA; Joshi RH; Wolff JE; Jonas BA
Cancer; 2021 Aug; 127(16):2943-2953. PubMed ID: 33934351
[TBL] [Abstract][Full Text] [Related]
40. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
Pasvolsky O; Shimony S; Ram R; Shimoni A; Shargian L; Avni B; Wolach O; Shochat T; Yerushalmi R; Amit O; Raanani P; Yeshurun M
Ann Hematol; 2022 Feb; 101(2):379-387. PubMed ID: 34628534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]